Coeptis Therapeutics (COEP) Competitors $7.62 +0.14 (+1.87%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$7.51 -0.11 (-1.43%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. CRDL, ATOS, QNTM, CCCC, CRBP, OPTN, FBRX, SAVA, TNYA, and VIRIShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Quantum Biopharma (QNTM), C4 Therapeutics (CCCC), Corbus Pharmaceuticals (CRBP), OptiNose (OPTN), Forte Biosciences (FBRX), Cassava Sciences (SAVA), Tenaya Therapeutics (TNYA), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Cardiol Therapeutics Atossa Genetics Quantum Biopharma C4 Therapeutics Corbus Pharmaceuticals OptiNose Forte Biosciences Cassava Sciences Tenaya Therapeutics Virios Therapeutics Cardiol Therapeutics (NASDAQ:CRDL) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media prefer CRDL or COEP? In the previous week, Coeptis Therapeutics had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 0 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score. Company Overall Sentiment Cardiol Therapeutics Neutral Coeptis Therapeutics Neutral Do institutionals & insiders hold more shares of CRDL or COEP? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate CRDL or COEP? Cardiol Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 427.70%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CRDL or COEP more profitable? Cardiol Therapeutics' return on equity of -209.63% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -209.63% -141.09% Coeptis Therapeutics N/A -282.39%-127.23% Which has more volatility & risk, CRDL or COEP? Cardiol Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500. Which has better earnings and valuation, CRDL or COEP? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-4.46Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.31 SummaryCardiol Therapeutics beats Coeptis Therapeutics on 7 of the 13 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.28M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-1.3121.5627.4020.24Price / SalesN/A281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book4.737.518.085.67Net Income-$10.88M-$55.05M$3.16B$248.47M7 Day Performance-2.06%4.71%2.84%3.32%1 Month Performance-19.62%4.89%3.69%5.20%1 Year Performance37.94%5.82%35.30%21.35% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.2979 of 5 stars$7.62+1.9%N/A+37.9%$26.28MN/A-1.312Gap UpCRDLCardiol Therapeutics2.0824 of 5 stars$1.28+3.2%$8.67+577.1%-21.0%$102.49MN/A-3.7620Positive NewsGap UpATOSAtossa Genetics1.48 of 5 stars$0.80+1.3%$6.17+670.8%-29.3%$102.04MN/A-3.818QNTMQuantum BiopharmaN/A$23.01-34.3%N/AN/A$101.76MN/A-1.44N/ACCCCC4 Therapeutics1.7402 of 5 stars$1.47+3.5%$12.00+716.3%-67.3%$100.83M$39.78M-1.00150CRBPCorbus Pharmaceuticals3.7472 of 5 stars$7.89-4.2%$50.88+544.8%-84.7%$100.83MN/A-1.8740Negative NewsOPTNOptiNose0.7569 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190FBRXForte Biosciences2.9506 of 5 stars$12.76-13.0%$61.00+378.1%+67,782.4%$96.51MN/A-0.785High Trading VolumeSAVACassava Sciences4.1866 of 5 stars$1.89-5.0%$54.50+2,783.6%-81.3%$96.13MN/A-1.2630TNYATenaya Therapeutics3.0917 of 5 stars$0.56-4.9%$6.25+1,018.9%-79.0%$95.50MN/A-0.48110VIRIVirios TherapeuticsN/A$4.90+2.1%$5.00+2.0%+1,911.7%$94.36MN/A-18.155 Related Companies and Tools Related Companies Cardiol Therapeutics Alternatives Atossa Genetics Alternatives Quantum Biopharma Alternatives C4 Therapeutics Alternatives Corbus Pharmaceuticals Alternatives OptiNose Alternatives Forte Biosciences Alternatives Cassava Sciences Alternatives Tenaya Therapeutics Alternatives Virios Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COEP Stock Alerts